Alternative dosing regimen for Reyataz (atazanavir) for treatment-naïve patients who can take ritonavir

On September 30, 2008, FDA approved an alternative dosing regimen for Reyataz (atazanavir) for HIV-1 infected treatment-naïve patients who can take ritonavir. The recommended dosage is Reyataz 300 mg with ritonavir 100 mg once daily for treatment-naïve patients. Revisions with respect to the new dosing regimen in treatment-naïve patients were added to the package insert. Other minor revisions were made throughout the label.

The revised label can be found at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8313. 

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration